102
Views
17
CrossRef citations to date
0
Altmetric
Urology

Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: Initial experience with Dysport™

, , , , , & show all
Pages 151-157 | Received 15 Nov 2009, Accepted 15 Jan 2010, Published online: 05 Mar 2010
 

Abstract

Objective. To evaluate the effect of intraprostatic botulinum toxin type A (BoNTA, Dysport™) injection on lower urinary tract symptoms, prostate-specific antigen (PSA), prostate volume (PV), peak urine flow rate (Qmax) and postvoiding residue (PVR), and to evaluate the role of PV in the treatment outcome. Material and methods. Seventy-two men with PSA < 4 ng/ml, International Prostate Symptom Score (IPSS) ≥ 8, Qmax < 12 ml/s and PV < 60 ml were enrolled. A total of 300–600 U Dysport was injected transperineally under transrectal ultrasound guidance. Initial IPSS, quality of life (QoL) score, Qmax and PVR were compared with their measures at 1, 6 and 12 months after the injection. Initial PSA and PV were compared with their values after 6 months. Parameters were also compared between patients with PV ≤ 30 ml and those with PV > 30 ml. Results. The mean age of participants was 63.5 years. At follow-up sessions, IPSS and QoL score were significantly decreased (p < 0.001). PVR reduced significantly and Qmax increased considerably (p < 0.001). PSA and PV substantially decreased after 6 months (p < 0.001). No serious complications were reported. Similar to patients with larger prostates, IPSS and QoL score decreased statistically significantly after 12 months in those with PV ≤ 30 ml; however, changes in PV, PSA, PVR and Qmax did not persist during 12 months' follow-up. Conclusions. The procedure is safe and efficacious and the results are comparable to previous experiences with Botox®. It seems that the toxin efficacy depends directly on PV in prostates < 60 ml.

Acknowledgements

Our special thanks go to the administrative staff of the Urology Research Center for their rigorous collaboration during the study. We are also grateful to Dr Laleh Montaser-Kouhsari and Dr Nima Baradaran for their priceless assistance in reviewing the manuscript. This study was supported in part by a grant from the Tehran University of Medical Sciences (no. 5381).

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.